Investors watching for signs of M&A activity from Gilead Sciences Inc. could be eyeing the big biotech even more closely after top-line phase II data revealed a missed primary endpoint for hepatitis B virus (HBV) contender GS-4774, prompting speculation that the Foster City, Calif.-based firm could tap other players to shore up its early but promising HBV pipeline.